MabCure Begins Clinical Trial for Antibody Technology for Use as Cancer Diagnostic

The technology, which MabCure hopes to commercialize first in Europe and then in the US, is an improvement over proteomics approaches, the company said.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.